A secondary aim of our experiments was to assess whether ALK and IGF-1R represent independent drug targets according to the criterion for combinatorial drug treatment developed by Bozic and Nowak15,16 such that drug resistance mechanisms for the two targets are independently distributed among cancer cell clones. The gene discussed is ALK; the disease is cancer.